Citius Pharmaceuticals, Inc. reported earnings results for the first quarter ended December 31, 2023. For the first quarter, the company reported net loss was USD 9.23 million compared to USD 3.59 million a year ago. Basic loss per share from continuing operations was USD 0.06 compared to USD 0.02 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6675 USD | +6.85% | -4.79% | -11.76% |
05-14 | Citius Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024 | CI |
04-26 | Citius Pharmaceuticals Launches $15 Million Offering | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.76% | 113M | |
+33.37% | 49.46B | |
+1.55% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.57% | 26.61B | |
-21.00% | 18.64B | |
+7.36% | 13.16B | |
+28.30% | 12.55B | |
+23.80% | 12.1B |
- Stock Market
- Equities
- CTXR Stock
- News Citius Pharmaceuticals, Inc.
- Citius Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023